What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cancer
His primary areas of study are Internal medicine, Immunology, Lupus erythematosus, Systemic lupus erythematosus and Surgery.
Internal medicine is represented through his Rheumatology, Connective tissue disease, Systemic disease, Cohort study and Immunopathology research.
The study incorporates disciplines such as Systemic lupus, Disease and Clinical significance in addition to Rheumatology.
His Lupus erythematosus research is multidisciplinary, incorporating perspectives in Randomized controlled trial, Intention-to-treat analysis, Family medicine, Physical therapy and Severity of illness.
David A. Isenberg focuses mostly in the field of Systemic lupus erythematosus, narrowing it down to topics relating to Anti-SSA/Ro autoantibodies and, in certain cases, Anti-nuclear antibody.
The concepts of his Surgery study are interwoven with issues in Lupus nephritis and Adverse effect.
His most cited work include:
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2280 citations)
- The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. (1673 citations)
- Systemic lupus erythematosus. (1376 citations)
What are the main themes of his work throughout his whole career to date?
David A. Isenberg mainly investigates Immunology, Internal medicine, Lupus erythematosus, Systemic lupus erythematosus and Antibody.
His research on Immunology frequently links to adjacent areas such as Disease.
His work deals with themes such as Gastroenterology and Surgery, which intersect with Internal medicine.
As part of the same scientific family, David A. Isenberg usually focuses on Lupus erythematosus, concentrating on Connective tissue disease and intersecting with Systemic disease and Immunopathology.
His Systemic lupus erythematosus study incorporates themes from Clinical trial and Discoid lupus erythematosus.
He has researched Antibody in several fields, including Molecular biology and Antigen.
He most often published in these fields:
- Immunology (48.74%)
- Internal medicine (43.33%)
- Lupus erythematosus (21.95%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (43.33%)
- Systemic lupus erythematosus (20.23%)
- Disease (13.33%)
In recent papers he was focusing on the following fields of study:
David A. Isenberg mainly focuses on Internal medicine, Systemic lupus erythematosus, Disease, Cohort and Rituximab.
The various areas that David A. Isenberg examines in his Internal medicine study include Gastroenterology and Lupus erythematosus.
His Lupus erythematosus research incorporates elements of Young adult and Severity of illness.
His Systemic lupus erythematosus research is multidisciplinary, incorporating elements of Body mass index and Arthritis.
His research integrates issues of Dermatology, Belimumab and Intensive care medicine in his study of Rituximab.
His Antibody study is focused on Immunology in general.
Between 2018 and 2021, his most popular works were:
- New therapies for systemic lupus erythematosus - past imperfect, future tense. (47 citations)
- A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. (32 citations)
- Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. (29 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
David A. Isenberg spends much of his time researching Internal medicine, Rituximab, Rheumatology, Systemic lupus erythematosus and Cohort.
David A. Isenberg applies his multidisciplinary studies on Internal medicine and In patient in his research.
His Rheumatology study also includes
- Frailty Index and related Systemic lupus,
- Hazard ratio which is related to area like Proportional hazards model, Criterion validity and Prospective cohort study.
His studies in Systemic lupus erythematosus integrate themes in fields like Cancer research, Tyrosine kinase, Bruton's tyrosine kinase, Immune system and B cell.
His Belimumab research is under the purview of Immunology.
His research in Immunology is mostly concerned with Avidity.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
